Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial

NCT05586074 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.

NCT NCT05586074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05586074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
March 3, 2023
Completion date
May 30, 2028
Enrollment
324 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, acute myeloid (aml)